To further enhance the effect of combining APR-246 with ICB, we tested dual ICB using a combination of antibodies that block PD-1 and cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), a strategy that has been shown to elicit a high response rate in patients with melanoma (19, 20). This evidence concerns the gene PDCD1 and melanoma.